Cantor Fitzgerald maintains Vertex stock at Overweight, $480 target
Cantor Fitzgerald reiterated its Overweight rating and a $480.00 price target for Vertex Pharmaceuticals Incorporated (NASDAQ ...
Acrivon Therapeutics initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Acrivon Therapeutics (ACRV) with an Overweight rating without a price target The company has two ...
KLA Corporation (KLAC) Faces Short-Term Headwinds in Semiconductor Equipment Market, Cantor Fitzgerald Sees Recovery in 2025
Investment firm Cantor Fitzgerald recently penned a research ... Shares were likely range-bound into DOC/BIS announcement, ...